Skip to main content

Diffuse Scleroderma clinical trials at UCSF

2 research studies open to eligible people

Showing trials for
  • Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    open to eligible people ages 18-85

    The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.

    Fresno, California and other locations

  • Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

    San Francisco, California and other locations

Our lead scientists for Diffuse Scleroderma research studies include .

Last updated: